DNA-Encoded Metabolic Transformation by Leveraging In Vivo Protein Production to Redefine Durability & Dosing Paradigms Beyond Incretin Agonism

  • Investigating a novel DNA-based platform for sustained in vivo GLP-1 production following a single administration
  • Examining DNA electroporation for delivery of brain-targeted incretin mimetics for precise hunger modulation
  • Assessing strategies for half-life extension of incretin to reduce dosing frequencies for improved patient adherence